IMVT - Immunovant, Inc.
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a wider fourth‑quarter loss than analysts expected.
Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026.
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m.
Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total transaction of $81,573.48. Following the completion of the sale, the chief technology officer directly owned 251,685 shares in the
Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings. Institutional and Insider Ownership 92.9% of Arcus Biosciences
Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.
Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint. Brepocitinib expands into lichen planopilaris Matt Gline, CEO of Roivant Sciences, said the companies are moving
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in a late-stage study.
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib's expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026 Immunovant's Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves' disease Immunovant remains focused on rapid advancement of IMVT-1402 in multiple indications Roivant will host an investor call to discuss these updates today, April 2, 2026, at 8:00 a.m.
Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.
Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Immunovant, Inc. (NASDAQ: IMVT - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $27.92 and last traded at $27.1690, with a volume of 109492 shares. The stock had previously closed at $27.05. The company